DDInter75 DDInter905
An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Salicylic acid
Salicylic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Aminosalicylic acid (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Droxidopa (Compound) and Droxidopa (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Droxidopa (Compound) and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Idelalisib
Aminosalicylic acid (Compound) resembles Droxidopa (Compound) and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Idelalisib